The stock in focus today has strong momentum behind it, perhaps enough to propel it past the returns of the overall market for the next 5 years. The company beat its EPS estimates by 27% in the 2022 third quarter. Moreover…
the U.S. Food and Drug Administration recently granted Emergency Use Authorization to Pfizer Inc. (PFE) and BioNTech SE’s (BNTX) Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, the third 3-µg dose in the three-dose primary series for children aged six months to four years of age.
This approval is yet another feather in the cap of PFE. The company has been a significant beneficiary of the pandemic.
In addition, PFE has been outperforming the broader market. PFE has gained 50.5% over the past five years and 9.6% over the past month, while the SPDR S&P 500 Trust ETF (SPY) has gained 49.5% over the past five years and marginally over the past month.
PFE has gained 9.2% over the past three months and 4.4% over the past six months to close the last trading session at $52.16.
Furthermore…
Continue reading at STOCKNEWS.com
